IP Verse

Boehringer Ingelheim competitive analysis

Loading summary...

Latest oppositions filed by Boehringer Ingelheim

Explore patent oppositions filed by Boehringer Ingelheim against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 23, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3842456
Interleukin-31 Monoclonal AntibodyZOETIS SERVICESJun 13, 2025
EP3653645
Interleukin-31 Monoclonal AntibodyZOETIS SERVICESMay 20, 2025
EP4107159
5-(3-(Ethylsulfonyl)Pyridin-2-Yl)-Pyrazolo[1,5-A]Pyrimidine Derivatives And Related Compounds As Pesticide And Insecticide Agents For Crop ProtectionPI INDUSTRIESJan 16, 2025
EP3300743
Methods Of Vaccine AdministrationZOETIS SERVICESMar 13, 2024
EP3733672
Heterocyclic Compounds And Noxious Arthropod Control Agent Containing SameSUMITOMO CHEMICALDec 20, 2023
EP3471766
Recombinant Non-Pathogenic Marek'S Disease Virus Constructs Encoding Infectious Laryngotracheitis Virus And Infectious Bursal Disease Virus AntigensINTERVETSep 12, 2023
EP3165600
Cell Culture Medium Comprising Small PeptidesLIFEAug 1, 2023
EP3874047
Carbon-Source Regulated Protein Production In A Recombinant Host CellLONZAJan 9, 2023
EP2833908
Mycoplasma Hyopneumoniae VaccineZOETISOct 3, 2022
EP3342786
Anti-Dll3 AntibodyCHUGAI SEIYAKU KABUSHIKI KAISHAMar 22, 2022

Latest patents of Boehringer Ingelheim opposed by its competitors

Explore Boehringer Ingelheim's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 23, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP2152341
Apr 2, 2025Atomizer, And Filter2
EP3539540
Dec 18, 2024Pharmaceutical Composition, Methods For Treating And Uses Thereof11
EP2488145
Apr 24, 2024Containers For Compositions Comprising Meloxicam1
EP3150200
Apr 10, 2024Pharmaceutical Composition, Pharmaceutical Dosage Form, Process For Their Preparation, Methods For Treating And Uses Thereof4
EP2395968
Jan 17, 2024Pharmaceutical Composition Comprising Glucopyranosyl Diphenylmethane Derivatives, Pharmaceutical Dosage Form Thereof, Process For Their Preparation And Uses Thereof For Improved Glycemic Control In A Patient19
EP2313087
Nov 22, 2023Pharmaceutical Dosage Form For Immediate Release Of An Indolinone Derivative3
EP3862003
Oct 25, 2023An Sglt-2 Inhibitor For Use In The Treatment Of A Metabolic Disorder In Feline Animals1
EP3110449
Jun 28, 2023Medical Use Of A Dpp-4 Inhibitor5
EP3485890
May 10, 2023Treatment Of Metabolic Disorders In Canine Animals1
EP3802922
Apr 26, 2023Novel Immune Checkpoint Inhibitors1

Latest publications and patents of Boehringer Ingelheim New

Explore the latest publications and patents granted to Boehringer Ingelheim, showcasing their recent innovations and technological advancements.

Last updated on: Oct 17, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Boehringer Ingelheim

EP4402138
Aug 27, 20253-Phenoxyazetidin-1-Yl-Heteroaryl Pyrrolidine Derivatives And The Use Thereof As MedicamentGranted
EP4603094
Aug 20, 2025New Combination Of Active Agents For The Treatment Of Progressive Fibrosing Interstitial Lung Diseases (Pf-Ild)Pending
EP4566621
Aug 20, 2025Dll3/Cd3 Binding Proteins For The Treatment Of CancerPending
EP4401738
Aug 20, 2025Medicament For Preventing And/Or Treating Dry EyePending
EP4596559
Aug 6, 2025Difluoromethyl-Pyridin-2-Yl TriazolesPending
EP4596558
Aug 6, 2025Difluoromethyl-Pyridin-2-Yl TriazolesPending
EP4594511
Aug 6, 2025Novel Transposase SystemPending
EP4593838
Aug 6, 2025Use Of Biomarkers In The Treatment Of Fibrotic Conditions With A Pde4B-InhibitorPending
EP4171563
Aug 6, 2025Tetrazole Derivatives As Trpa1 InhibitorsGranted
EP4284511
Jul 16, 2025Azaquinolines As Inhibitors Of Cd38Granted

Latest PTAB cases involving Boehringer Ingelheim

Discover the latest PTAB cases involving Boehringer Ingelheim, highlighting their recent legal challenges and patent disputes.

Last updated on: Oct 23, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Boehringer Ingelheim

PGR2022-00037May 2, 2022SANDOZBOEHRINGER INGELHEIMInstitution Denied
PGR2022-00021Dec 22, 2021BOEHRINGER INGELHEIM ANIMAL HEALTH USAKANSAS STATE UNIVERSITY RESEARCH FOUNDATIONInstitution Denied
PGR2020-00076Jul 22, 2020BOEHRINGER INGELHEIM ANIMAL HEALTH USAKANSAS STATE UNIVERSITY RESEARCH FOUNDATIONFinal Written Decision
IPR2019-00374Nov 30, 2018INTERVETBOEHRINGER INGELHEIM VETMEDICAInstitution Denied
IPR2019-00381Nov 30, 2018INTERVETBOEHRINGER INGELHEIM VETMEDICATerminated-Settled
IPR2018-01788Sep 24, 2018INTERVETBOEHRINGER INGELHEIM VETMEDICAInstitution Denied
IPR2018-01789Sep 24, 2018INTERVETBOEHRINGER INGELHEIM VETMEDICAInstitution Denied
IPR2017-02029Aug 31, 2017BOEHRINGER INGELHEIM PHARMACEUTICALSGENENTECHTerminated-Settled
IPR2017-02031Aug 31, 2017BOEHRINGER INGELHEIM PHARMACEUTICALSGENENTECHTerminated
IPR2017-02032Aug 31, 2017BOEHRINGER INGELHEIM PHARMACEUTICALSGENENTECHTerminated

Peer Comparison New

IP litigation analysis comparing Boehringer Ingelheim with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
BOEHRINGER INGELHEIM ANIMAL HEALTH USA16302 -
CEVA SANTE ANIMALE213 - -
INTERVET113441
LABORATORIOS HIPRA7 - - -